Printer Friendly

BIOCHEM PHARMA PRESIDENT TO COMMENT ON RESULTS OF PHASE I/II TESTS ON 3TC

 BIOCHEM PHARMA PRESIDENT TO COMMENT ON RESULTS
 OF PHASE I/II TESTS ON 3TC
 Francesco Bellini, president and chief executive officer of BioChem Pharma Inc., will give his comments on the results of the phase I/II clinical tests of the anti-AIDS drug 3TC. These results will have been made public a few hours earlier at the International Conference on AIDS in Amsterdam. The meeting with the press will take place on Monday, July 20, 1992, at noon, at Centre multimedia de Montreal, Room 053, Teleport de Montreal, 1205 Papineau St.
 WHAT: Comments on the results of phase I/II clinical tests on 3TC
 WHO: Dr. Francesco Bellini
 WHEN: Monday, July 20, 1992, at 12 p.m.
 WHERE: Centre multimedia de Montreal
 Room 053
 Teleport de Montreal
 1205 Papineau St.
 Montreal
 CONTACT: Michele Roy or Gerard Berube of NATIONAL Public Relations, 514-843-7171, for BioChem Pharma.
 -0- 7/20/92
 (BCHXF) CO: BioChem Pharma Inc. ST: Quebec IN: MTC SU:


KD-SH -- NY014 -- 0611 07/20/92 09:48 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 20, 1992
Words:168
Previous Article:TECHTEAM ANNOUNCES RECORD INCREASE IN REVENUES AND EARNINGS FOR THE SECOND QUARTER AND THE FIRST SIX MONTHS OF 1992
Next Article:VIEWLOGIC SYSTEMS REPORTS SECOND-QUARTER RESULTS; NET INCOME INCREASES 134 PERCENT ON 30 PERCENT REVENUE INCREASE
Topics:


Related Articles
3TC ACTIVE AGAINST HEPATITIS B VIRUS
BIOCHEM PHARMA WITHDRAWS INTERNATIONAL EQUITY OFFERING
PRESENTATION OF PRELIMINARY DATA ON 3TC IN THE TREATMENT OF HIV INFECTION AT THE INTERNATIONAL CONFERENCE ON AIDS IN AMSTERDAM
3TC RESULTS TO BE SUBMITTED TO REGULATORY AUTHORITIES TO PROCEED TO DEFINITIVE PHASE OF TRIALS
3TC PROCEEDS TO PHASE II/III CLINICAL TRIALS
3TC PROCEEDS TO PHASE II/III CLINICAL TRIALS
BIOCHEM PHARMA: INTERIM DATA FROM PHASE I/II 3TC TRIALS PRESENTED AT MONTREAL HIV MEETING
BIOCHEM IS STILL GROWING
BIOCHEM IS STILL GROWING
BIOCHEM PHARMA'S MANAGEMENT REVIEWS COMPANY'S FIVE-YEAR GROWTH PROSPECTS.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters